Fundz

Cardurion Pharmaceuticals Announces Investment Of Up To $300 Million From Bain Capital

PRIVATEOct 27, 2021

Round Type

Venture

BostonBiotechnologyData And AnalyticsHealth CareScience And Engineering

Description

Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity. Bain Capital joins existing investors, Takeda Pharmaceuticals and Polaris Partners, in supporting the evolution of Cardurion into a leading cardiovascular biotechnology company.

Who else raised in Data And Analytics and Science And Engineering around the same time

Companies in the same sectors as Cardurion Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.

  • Stilla Technologies raised an undisclosed amount on November 23, 2021.
  • American Bitcoin raised $18M on October 20, 2021.
  • Envisagenics raised $19M on October 19, 2021.
  • Exscientia raised $510M (Post-IPO Equity) on October 5, 2021.
  • Envisagenics raised an undisclosed amount (Series A) on September 29, 2021.
  • Delix Therapeutics raised $70M (Series A) on September 27, 2021.

Who to call at Cardurion Pharmaceuticals, and when

A new round usually means Cardurion Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Cardurion Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Cardurion Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Cardurion Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Cardurion Pharmaceuticals

Location

78 BLANCHARD ROAD, SUITE 200

Boston, Massachusetts, United States

About

Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in-house drug discovery and our office of strategy and have concluded foundational partnerships with key strategics and investors, including an up to $300 million dollar investment from Bain Capital to support current programs and pipeline growth. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Cardurion Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsPeter L., Executive Officer, Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Cardurion Pharmaceuticals's next move

See what Strategic adds

Cardurion Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.